Serum levels and genetic variation of IL-35 are associated with multiple sclerosis: a population-based case-control study.
EBI3
High resolution melt analysis
IL-35
Multiple sclerosis
Polymorphism
Journal
Immunologic research
ISSN: 1559-0755
Titre abrégé: Immunol Res
Pays: United States
ID NLM: 8611087
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
12
05
2021
accepted:
10
10
2021
pubmed:
29
10
2021
medline:
3
5
2022
entrez:
28
10
2021
Statut:
ppublish
Résumé
This study aimed to investigate the association between serum levels and polymorphic variants of IL-35 with susceptibility, clinical features, and disease severity in multiple sclerosis (MS) patients.This case-control study recruited 186 MS patients and 195 sex- and age-matched healthy controls. Serum levels and polymorphic variants of IL-35 were determined by ELISA and restriction fragment length polymorphism (RFLP)-PCR or high resolution melting (HRM) analysis methods, respectively. In addition, by in silico analysis, we evaluated the location and function of the polymorphism.Serum levels of IL-35 were significantly lower in the patients than those of healthy controls (49.3 ± 3.7 vs. 69.5 ± 7.8, p = 0.009). EBI3 rs4740 polymorphism of IL-35 was associated with 2.2-fold increased risk of MS susceptibility (95% CI, 1.3-3.9, p = 0.005). However, there were no differences in the genotype distribution and allele frequencies of IL-35 rs568408 between the patients and controls (p > 0.05). In silico results showed that variation in IL-12A and EBI3 may affect on protein pathways of the cells and different components of the immune system such as NF-κB and INF-γ.The results show that IL-35 polymorphisms might be a genetic risk factor for the development of MS.
Identifiants
pubmed: 34708312
doi: 10.1007/s12026-021-09246-9
pii: 10.1007/s12026-021-09246-9
doi:
Substances chimiques
Interleukins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
75-85Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Morsaljahan Z, Rafiei A, Valadan R, Abedini M, Pakseresht M, Khajavi R. Association between interleukin-32 polymorphism and multiple sclerosis. J Neurol Sci. 2017;379:144–50.
doi: 10.1016/j.jns.2017.05.045
Mubeen H, Jabeen S, Shoaib S, Shoaib MW, Raza S. Multiple sclerosis: genetic factors, risk and prevalence. Mult Scler. 2016;2(3).
Goldenberg MM. Multiple sclerosis review. Pharmacol Ther. 2012;37(3):175.
Farrokhi M, Rezaei A, Amani-Beni A, Etemadifar M, Kouchaki E, Zahedi A. Increased serum level of IL-37 in patients with multiple sclerosis and neuromyelitis optica. Acta Neurol Belg. 2015;115(4):609–14.
doi: 10.1007/s13760-015-0491-3
Jafarzadeh A, Jamali M, Mahdavi R, Ebrahimi H, Hajghani H, Khosravimashizi A, et al. Circulating levels of interleukin-35 in patients with multiple sclerosis: evaluation of the influences of FOXP3 gene polymorphism and treatment program. J Mol Neurosci. 2015;55(4):891–7.
doi: 10.1007/s12031-014-0443-z
Sambucci M, Gargano F, De Rosa V, De Bardi M, Picozza M, Placido R, et al. FoxP3 isoforms and PD-1 expression by T regulatory cells in multiple sclerosis. Sci Rep. 2018;8(1):3674.
doi: 10.1038/s41598-018-21861-5
Jing S, Song Y, Song J, Pang S, Quan C, Zhou L, et al. Responsiveness to low-dose rituximab in refractory generalized myasthenia gravis. J Neuroimmunol. 2017;311:14–21.
doi: 10.1016/j.jneuroim.2017.05.021
Machado-Santos J, Saji E, Tröscher AR, Paunovic M, Liblau R, Gabriely G, et al. The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells. Brain. 2018;141(7):2066–82.
doi: 10.1093/brain/awy151
Choi SR, Howell OW, Carassiti D, Magliozzi R, Gveric D, Muraro PA, et al. Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. Brain. 2012;135(10):2925–37.
doi: 10.1093/brain/aws189
Li X, Mai J, Virtue A, Yin Y, Gong R, Sha X, et al. IL-35 is a novel responsive anti-inflammatory cytokine—a new system of categorizing anti-inflammatory cytokines. PloS One. 2012;7(3):e33628.
doi: 10.1371/journal.pone.0033628
Wu H, Li P, Shao N, Ma J, Ji M, Sun X, et al. Aberrant expression of Treg-associated cytokine IL-35 along with IL-10 and TGF-β in acute myeloid leukemia. Oncol Lett. 2012;3(5):1119–23.
doi: 10.3892/ol.2012.614
Lin Y, Xue Y, Huang X, Lu J, Yang Z, Ye J, et al. Association between interleukin-35 polymorphisms and coronary heart disease in the Chinese Zhuang population: a case–control study. Coron Artery Dis. 2018;29(5):423–8.
doi: 10.1097/MCA.0000000000000635
Guan S-Y, Liu L-N, Mao Y-M, Zhao C-N, Wu Q, Dan Y-L, et al. Association between Interleukin 35 gene single nucleotide polymorphisms and systemic lupus erythematosus in a Chinese Han population. Biomolecules. 2019;9(4):157.
doi: 10.3390/biom9040157
Lovett-Racke AE, Racke MK. Role of IL-12/IL-23 in the pathogenesis of multiple sclerosis. Neuroinflammation. Elsevier; 2018. p. 115–39.
Choi JK, Egwuagu CE. Interleukin 35 Regulatory B Cells. J. Mol. Biol. 2021;433(1)166607.
Yazdani Z, Rafiei A, Golpour M, Zafari P, Moonesi M, Ghaffari S. IL-35, a double-edged sword in cancer. J Cell Biochem. 2020;121(3):2064–76.
doi: 10.1002/jcb.29441
Zhang D-Q, Jia K, Wang R, Li T, Zhao N, Yang L-N, et al. Decreased serum IL-27 and IL-35 levels are associated with disease severity in neuromyelitis optica spectrum disorders. J Neuroimmunol. 2016;293:100–4.
doi: 10.1016/j.jneuroim.2016.03.004
Miteva L, Trenova A, Slavov G, Stanilova S. IL12B gene polymorphisms have sex-specific effects in relapsing–remitting multiple sclerosis. Acta Neurol Belg. 2019;119(1):83–93.
doi: 10.1007/s13760-018-01066-3
Chen T, Liang W, Gao L, Wang Y, Liu Y, Zhang L, et al. Association of single nucleotide polymorphisms in interleukin 12 (IL-12A and-B) with asthma in a Chinese population. Hum Immunol. 2011;72(7):603–6.
doi: 10.1016/j.humimm.2011.03.018
Wang EY, Yang Q, Liao ZG. Association of polymorphisms in interleukin (IL)-12 A and-B genes with rheumatoid arthritis in a C hinese population. Clin Exp Immunol. 2015;180(1):83–9.
doi: 10.1111/cei.12563
Guo T, Yang S, Liu N, Wang S, Cui B, Ning G. Association study of interleukin-12A gene polymorphisms with Graves’ disease in two Chinese populations. Clin Endocrinol. 2011;74(1):125–9.
doi: 10.1111/j.1365-2265.2010.03905.x
Wang J, Lu L, Huang K, Wei G, Tang Y. Associations of Epstein-Barr virus-induced gene 3 polymorphisms and expression with osteosarcoma risk. Int J Clin Exp Pathol. 2016;9(10):10721–7.
Posadas-Sanchez R, Perez-Hernandez N, Angeles-Martinez J, Lopez-Bautista F, Villarreal-Molina T, Rodriguez-Perez JM, et al. Interleukin 35 polymorphisms are associated with decreased risk of premature coronary artery disease, metabolic parameters, and IL-35 levels: the Genetics of Atherosclerotic Disease (GEA) Study. Mediators Inflamm. 2017;2017:6012795. https://doi.org/10.1155/2017/6012795 .
doi: 10.1155/2017/6012795
pubmed: 28321150
pmcid: 5340958
Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162–73.
doi: 10.1016/S1474-4422(17)30470-2
Yates AD, Achuthan P, Akanni W, Allen J, Allen J, Alvarez-Jarreta J, et al. Ensembl 2020. Nucleic acids Res. 2020;48(D1):D682–8.
pubmed: 31691826
Capriotti E, Fariselli P, Casadio R. I-Mutant2. 0: predicting stability changes upon mutation from the protein sequence or structure. Nucleic acids Res. 2005;33(suppl_2):W306-W10.
Xu Z, Taylor JA. SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. Nucleic acids Res. 2009;37(suppl_2):W600-W5.
Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic acids Res. 2010;38(suppl_2):W214-W20.
Kimura K. Regulatory T cells in multiple sclerosis. Clinical and Experimental Neuroimmunology.
Jones AP, Trend S, Byrne SN, Fabis-Pedrini MJ, Geldenhuys S, Nolan D, et al. Altered regulatory T-cell fractions and Helios expression in clinically isolated syndrome: clues to the development of multiple sclerosis. Clin Transl Immunol. 2017;6(5):e143.
doi: 10.1038/cti.2017.18
Nakano S, Morimoto S, Suzuki S, Tsushima H, Yamanaka K, Sekigawa I, et al. Immunoregulatory role of IL-35 in T cells of patients with rheumatoid arthritis. Rheumatology. 2015;54(8):1498–506.
doi: 10.1093/rheumatology/keu528
Chen C, Xu H, Peng Y, Luo H, Huang G-X, Wu X-J, et al. Elevation in the counts of IL-35-producing B cells infiltrating into lung tissue in mycobacterial infection is associated with the downregulation of Th1/Th17 and upregulation of Foxp3+ Treg. Sci Rep. 2020;10(1):1–14.
doi: 10.1038/s41598-019-56847-4
Wang R-X, Yu C-R, Dambuza IM, Mahdi RM, Dolinska MB, Sergeev YV, et al. Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nat Med. 2014;20(6):633–41.
doi: 10.1038/nm.3554
Kang M, Choi JK, Jittayasothorn Y, Egwuagu CE. Interleukin 35-producing exosomes suppress neuroinflammation and autoimmune uveitis. Front Immunol. 2020;11:1051.
doi: 10.3389/fimmu.2020.01051
Knippenberg S, Peelen E, Smolders J, Thewissen M, Menheere P, Tervaert JWC, et al. Reduction in IL-10 producing B cells (Breg) in multiple sclerosis is accompanied by a reduced naive/memory Breg ratio during a relapse but not in remission. J Neuroimmunol. 2011;239(1–2):80–6.
doi: 10.1016/j.jneuroim.2011.08.019
Romero-Barrios N, Legascue MF, Benhamed M, Ariel F, Crespi M. Splicing regulation by long noncoding RNAs. Nucleic acids Res. 2018;46(5):2169–84.
doi: 10.1093/nar/gky095
Gao P, Su Z, Lv X, Zhang J. Interluekin-35 in asthma and its potential as an effective therapeutic agent. Mediators inflamm. 2017;2017.
Fogel O, Rivière E, Seror R, Nocturne G, Boudaoud S, Ly B et al. Role of the IL-12/IL-35 balance in patients with Sjögren syndrome. J. Allergy Clin. Immunol. 2018;142(1):258–68. e5.
Shi Y, Zhang S, Xue Y, Yang Z, Lin Y, Liu L et al. IL-35 polymorphisms and cognitive decline did not show any association in patients with coronary heart disease over a 2-year period: a retrospective observational study (STROBE compliant). Medicine. 2020;99(31).
Posadas-Sánchez R, del Carmen González-Salazar M, Cardoso-Saldaña G, Criales-Vera SA, Reyes-Barrera J, Pérez-Hernández N, et al. Epstein-Barr virus-induced gene 3 (EBI3) single nucleotide polymorphisms and their association with central obesity and risk factors for cardiovascular disease: the GEA study. Cytokine. 2020;135:155225.
doi: 10.1016/j.cyto.2020.155225
Liu X, Ren H, Guo H, Wang W, Zhao N. Interleukin-35 has a tumor-promoting role in hepatocellular carcinoma. Clin Exp Immunol. 2021;203(2):219–29.
doi: 10.1111/cei.13535
Liu L, Xu Y, Liu Z, Chen J, Zhang Y, Zhu J, et al. IL12 polymorphisms, HBV infection and risk of hepatocellular carcinoma in a high-risk Chinese population. Int J Cancer Res. 2011;128(7):1692–6.
doi: 10.1002/ijc.25488
Posadas-Sánchez R, Pérez-Hernández N, Angeles-Martínez J, López-Bautista F, Villarreal-Molina T, Rodríguez-Pérez JM et al. Interleukin 35 polymorphisms are associated with decreased risk of premature coronary artery disease, metabolic parameters, and IL-35 levels: the genetics of atherosclerotic disease (GEA) study. Mediators Inflamm. 2017;2017.